Skip to main content
SpringerLink
Log in

Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Objective. To investigate the effects of desferrioxamine (DFO) infusion on chronic disease anemia (CDA) of rheumatoid arthritis (RA) by evaluating interleukin-6 (IL-6) and erythropoietin (EPO) production.Patients and methods. Five patients with RA and CDA (group I) were treated with DFO, 500 mg daily, through a continuous 10-h subcutaneous infusion 5 days a week for 4 weeks. One month after withdrawal, DFO was resumed in all five group I patients (group II) with an increase to 1 g daily following the previous treatment schedule. Clinical and laboratory parameters were evaluated weekly during the two study periods. Serum EPO was measured by radioimmunoassay. IL-6 was detected by the enzyme-linked immunoabsorbent assay method.Results. No significant variations in hematological parameters, IL-6 or EPO levels were observed in group I patients. After 1 week of DFO 1 g daily, reticulocyte counts and EPO improved significantly. Hemoglobin and hematocrit rose significantly after 3 weeks of 1 g daily DFO therapy. Four weeks after DFO withdrawal, EPO, reticulocyte counts, hemoglobin and hematocrit returned to baseline levels. A significant improvement in the clinical parameters of disease activity was observed, particularly in group II patients.Conclusion. DFO improves CDA in RA patients. The beneficial effects on erythropoiesis seem to be related to improved EPO responsiveness to the anemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baer AN, Dessypiris EN, Krantz SB (1971) The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum 19:209–223

    Google Scholar 

  2. Baer AN, Dessypiris EN, Goldwasser E, Krantz SB (1987) Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 66:559–564

    PubMed  Google Scholar 

  3. Salvarani C, Casali B, Salvo D, Brunati C, Macchioni PL, Massai G, Lasagni D, Rivasi P, Portioli I (1991) The role of interleukin-1, erythropoietin and red cells bound immunoglobulins in the anaemia of rheumatoid arthritis. Clin Exp Rheumatol 9:241–246

    PubMed  Google Scholar 

  4. Salvarani C, Lasagni D, Casali B, Macchioni PL, Boiardi L, Rossi F, Rivasi P, Portioli I (1991) Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anaemia of chronic disease. J Rheumatol 18:1168–1171

    PubMed  Google Scholar 

  5. Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris RR, Schinitzer TJ, Boccagno JA, Krantz SB (1990) Multicenter study of recombinant human erythropoietin in correction of anaemia in rheumatoid arthritis. Am J Med 89:161–168

    PubMed  Google Scholar 

  6. Faquin WC, Schneider TJ, Goldberg MA (1992) Effects of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79:1987–1994

    PubMed  Google Scholar 

  7. Magaró M, Zoli A, Altomonte L, Mirone L, Corvino G, Storti S, Marra R, Ricerca BM, Pagano L, Dicesare L (1990) Iron chelation in rheumatoid arthritis: clinical and laboratory evaluation. Ann Rheum Dis 49:268–271

    Google Scholar 

  8. Giordano N, Sancasciani S, Borghi C, Fioravanti A, Marcolongo R (1986) Antianemic and potential anti-inflammatory activity of desferrioxamine: possible usefulness in rheumatoid arthritis. Clin Exp Rheumatol 4:25–29

    PubMed  Google Scholar 

  9. Vreugdenhil G, Kontoghiorghess GJ, Van Eijk HG, Swaak AJK (1991) Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Exp Rheumatol 9:35–40

    PubMed  Google Scholar 

  10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    PubMed  Google Scholar 

  11. Propper RD, Shurin SB, Nathan DG (1976) Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 294:1421–1423

    PubMed  Google Scholar 

  12. Wang GL, Semenza GL (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia inducible factor 1 DNA binding activity: implications for models of hypoxia signal transduction. Blood 82:3610–3615

    PubMed  Google Scholar 

  13. Dagupta B, Corkill M, Kirkam B, Gibson T, Panayi G (1992) Serial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19:22–25

    PubMed  Google Scholar 

  14. Polson RJ, Jawed A, Bomford A, Berry H, Williams R (1985) Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. B M J 291:448

    Google Scholar 

  15. Blake DR, WiDyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JMC, Rowley D, Halliwell B, Cornish A, Hider RC (1985) Cerebral and ocular toxicity induced by desferrioxamine. Q J M 219:345–355

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2^ Divisione di Medicina, Unita' Reumatologica, Azienda Ospedaliera Arcispedale S. Maria Nuova, V. le Umberto 1° n50, 1-42100, Reggio Emilia, Italy

    C. Salvarani, L. Boiardi, P. Macchioni & I. Portioli

  2. Centro Trasfusionale Azienda Ospedaliera Arcispedale S. Maria, Nuova Reggio Emilia, Italy

    R. Baricchi & D. Lasagni

  3. Laboratorio Tossicologico Unificato, USL di Reggio Emilia, Scandiano, Italy

    R. Piccinini

  4. Divisione di Nefrologia e Dialisi, Ospedale Niguarda Ca'Granda, Milan, Italy

    C. Brunati

Authors
  1. C. Salvarani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Baricchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Lasagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Boiardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Piccinini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Brunati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Macchioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I. Portioli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salvarani, C., Baricchi, R., Lasagni, D. et al. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol Int 16, 45–48 (1996). https://doi.org/10.1007/BF01816434

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01816434

Key words

Search

Navigation